{"id":1342,"date":"2026-07-05T06:54:15","date_gmt":"2026-07-05T06:54:15","guid":{"rendered":"https:\/\/drshintani.com\/wordpress\/?p=1342"},"modified":"2026-07-05T06:57:24","modified_gmt":"2026-07-05T06:57:24","slug":"when-is-weight-loss-not-healthy-what-dr-shintani-says-about-ozempic-and-glp-1-drugs","status":"publish","type":"post","link":"https:\/\/drshintani.com\/wordpress\/2026\/07\/05\/when-is-weight-loss-not-healthy-what-dr-shintani-says-about-ozempic-and-glp-1-drugs\/","title":{"rendered":"When Is Weight Loss Not Healthy? What Dr. Shintani Says About Ozempic and GLP-1 Drugs"},"content":{"rendered":"\n

Ozempic<\/a>. Wegovy. Mounjaro. Over the past two years, GLP-1 receptor agonist drugs \u2014 commonly known by their brand names \u2014 have become some of the most prescribed and most talked-about medications in the world. Celebrities have credited them with dramatic weight loss. Pharmaceutical companies are reporting record profits. And millions of people with diabetes and obesity are turning to these drugs as a first-line solution.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

But there is a question that is not being asked loudly enough: when is weight loss not healthy?<\/p>\n\n\n\n

Dr. Terry Shintani, a board-certified physician and Harvard-trained nutritionist who has spent decades helping patients achieve sustainable weight loss through diet and lifestyle, believes the conversation around GLP-1 drugs is missing something critical \u2014 and that the most important thing is not whether these drugs work, but whether the weight loss they produce is truly good for the body.<\/p>\n\n\n\n

What GLP-1 Drugs Actually Do<\/strong><\/p>\n\n\n\n

GLP-1 stands for glucagon-like peptide-1 \u2014 a hormone naturally produced in the gut after eating that signals the brain to feel full, stimulates insulin secretion, and slows the emptying of the stomach. Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) work by mimicking or enhancing this hormone’s effects \u2014 essentially suppressing appetite, improving blood sugar regulation, and inducing weight loss.<\/p>\n\n\n\n

On paper, this sounds straightforward. And for many patients, these drugs do produce meaningful results: lower blood sugar, significant weight reduction, and in some studies, reduced cardiovascular risk. They are legitimate medical tools, and Dr. Shintani acknowledges their value \u2014 particularly for patients with severe obesity or poorly controlled type 2 diabetes who have not responded to lifestyle interventions alone.<\/p>\n\n\n\n

But the full picture is more complicated.<\/p>\n\n\n\n

The Hidden Risks of Drug-Induced Weight Loss<\/strong><\/p>\n\n\n\n

1. Malnutrition from suppressed appetite<\/strong><\/p>\n\n\n\n

GLP-1 drugs work primarily by making people not want to eat. While this sounds appealing to anyone who has struggled with overeating, the problem is that the body still needs adequate nutrition \u2014 protein, essential fats, vitamins, and minerals \u2014 to function properly. When appetite is suppressed dramatically, many people are not getting enough of these essential nutrients, even as the number on the scale drops.<\/p>\n\n\n\n

The result can be nutritional deficiencies that affect energy levels, immune function, bone density, and organ health \u2014 none of which show up immediately, but accumulate over time.<\/p>\n\n\n\n

2. Muscle loss and sagging skin<\/strong><\/p>\n\n\n\n

Rapid weight loss \u2014 regardless of how it is achieved \u2014 carries the risk of losing lean muscle mass along with fat. When the body is not receiving adequate protein and is losing weight quickly, it often breaks down muscle tissue for energy. This leads to what is sometimes called “Ozempic face” or “Ozempic body” \u2014 the sagging, deflated appearance that many people report after significant drug-induced weight loss.<\/p>\n\n\n\n

Muscle loss is not just cosmetic. Muscle tissue is metabolically active \u2014 it burns calories at rest, supports insulin sensitivity, and protects joints and bones. Losing it accelerates aging and makes weight regain more likely when the drug is stopped.<\/p>\n\n\n\n

3. Increased risk of serious medical conditions<\/strong><\/p>\n\n\n\n

This is perhaps the most sobering part of the conversation. GLP-1 receptor agonist drugs carry FDA warnings for several potentially serious conditions:<\/p>\n\n\n\n